Guardant Health (GH) Set to Announce Quarterly Earnings on Thursday

Guardant Health (NASDAQ:GHGet Rating) is scheduled to release its earnings data after the market closes on Thursday, May 5th. Analysts expect Guardant Health to post earnings of ($1.21) per share for the quarter. Guardant Health has set its FY 2022 guidance at EPS.Persons interested in participating in the company’s earnings conference call can do so using this link.

Guardant Health (NASDAQ:GHGet Rating) last announced its earnings results on Wednesday, February 23rd. The company reported ($0.89) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.13) by $0.24. Guardant Health had a negative return on equity of 53.91% and a negative net margin of 108.57%. The business had revenue of $108.10 million for the quarter, compared to analysts’ expectations of $98.72 million. During the same period in the prior year, the business posted ($0.94) earnings per share. The firm’s revenue was up 38.1% on a year-over-year basis. On average, analysts expect Guardant Health to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Shares of GH stock opened at $64.69 on Thursday. The business’s 50 day simple moving average is $64.22 and its 200 day simple moving average is $83.16. Guardant Health has a one year low of $46.87 and a one year high of $166.20. The stock has a market capitalization of $6.59 billion, a PE ratio of -16.17 and a beta of 0.68. The company has a debt-to-equity ratio of 1.76, a current ratio of 5.72 and a quick ratio of 5.57.

In related news, Director Stanley J. Meresman sold 4,934 shares of the stock in a transaction on Thursday, March 10th. The stock was sold at an average price of $58.74, for a total value of $289,823.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 5.80% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GH. Legal & General Group Plc increased its position in shares of Guardant Health by 31.4% during the 4th quarter. Legal & General Group Plc now owns 109,376 shares of the company’s stock valued at $10,940,000 after purchasing an additional 26,114 shares during the last quarter. Stifel Financial Corp increased its position in shares of Guardant Health by 29.2% during the 4th quarter. Stifel Financial Corp now owns 75,818 shares of the company’s stock valued at $7,583,000 after purchasing an additional 17,146 shares during the last quarter. UBS Group AG increased its position in shares of Guardant Health by 0.9% during the 3rd quarter. UBS Group AG now owns 26,575 shares of the company’s stock valued at $3,323,000 after purchasing an additional 243 shares during the last quarter. Amalgamated Bank increased its position in shares of Guardant Health by 16.7% during the 4th quarter. Amalgamated Bank now owns 18,975 shares of the company’s stock valued at $1,898,000 after purchasing an additional 2,714 shares during the last quarter. Finally, Marshall Wace LLP purchased a new stake in shares of Guardant Health during the 4th quarter valued at $396,000. 90.88% of the stock is owned by institutional investors and hedge funds.

Several analysts recently commented on GH shares. Cowen reduced their target price on Guardant Health from $170.00 to $110.00 and set an “outperform” rating on the stock in a report on Thursday, February 24th. Citigroup reduced their target price on Guardant Health from $180.00 to $120.00 and set a “buy” rating on the stock in a report on Thursday, February 24th. SVB Leerink cut their price target on Guardant Health from $170.00 to $140.00 and set an “outperform” rating on the stock in a report on Thursday, February 24th. Canaccord Genuity Group cut their price target on Guardant Health from $180.00 to $165.00 and set a “buy” rating on the stock in a report on Thursday, February 24th. Finally, Wells Fargo & Company cut their price target on Guardant Health from $150.00 to $115.00 and set an “overweight” rating on the stock in a report on Thursday, February 24th. One analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have issued a buy rating to the company. According to MarketBeat.com, Guardant Health currently has an average rating of “Buy” and a consensus target price of $138.50.

Guardant Health Company Profile (Get Rating)

Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients.

Read More

Earnings History for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.